Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 214 people in total — 107 received lesinurad (400 mg) and 107 received a placebo (a dummy treatment with no active ingredient). The trial was measuring how many participants reached a specific level of uric acid in their blood — uric acid being a substance that builds up in some people and can cause problems in the joints. The target level the trial was tracking was a blood uric acid reading below 6.0 mg/dL (milligrams per decilitre, a standard unit of measurement). Not everyone finished the study: 84 people in the lesinurad group and 94 in the placebo group completed it. The reported data shows that, out of the participants measured for the main outcome, 32 people in the lesinurad 400 mg group reached a blood uric acid level below 6.0 mg/dL, compared with 2 people in the placebo group. No other outcome measures were included in the structured data provided, so further details beyond this primary result were not reported in the data available here. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 35835008) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Gout Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are able to understand what the study involves, accept the risks, and are willing to sign a consent form before anything begins.
- You have been diagnosed with gout according to a recognised set of medical classification guidelines.
- Your uric acid level in your blood was measured at 6.5 mg/dL or higher at two early visits in the study.
- You are able to take a preventive medication for gout flares, such as colchicine or an anti-inflammatory painkiller (with or without a stomach-protecting medicine).
- You have a history — either recorded by a doctor or reported by yourself — of not being able to tolerate, or having a medical reason not to take, either allopurinol or febuxostat (common gout medicines).
- Your body mass index (a measure of weight relative to height) is below 45.
Who may not be able to join:
- You are currently taking any other approved medication specifically prescribed to lower uric acid for gout.
- You have a confirmed or suspected history of kidney stones.
- You are pregnant or breastfeeding.
- You drink more than 14 alcoholic drinks per week (for example, one drink equals a small glass of wine, a standard can of beer, or a single shot of spirits).
- You have a history or suspicion of drug misuse within the past 5 years.
- You need, or may need, medications that suppress or alter your immune system.
- You have a known or suspected HIV infection.
- You have tested positive for an active hepatitis B or hepatitis C infection.
- You have been diagnosed with cancer in the past 5 years, unless it was a type of non-melanoma skin cancer that was fully treated with no return, or treated cervical cell changes or early-stage cervical cancer.
- In the past 12 months you have had unstable chest pain, severe heart failure, a heart attack, a stroke, or a blood clot in a vein; or you are currently taking blood-thinning medication.
- You have high blood pressure that is not well controlled.
- Your kidneys are not working well enough (confirm with trial site for the specific measurement used).
- You have an active stomach ulcer that needs treatment.
- You have active liver disease or your liver is not functioning properly.
- You regularly take more than 325 mg of aspirin (or similar salicylate medicines) per day.
- You are currently taking valpromide, progabide, or valproic acid (certain medications used for conditions such as epilepsy).
- You have taken part in another clinical trial or received an experimental treatment within the past 8 weeks (or longer, depending on the medication involved).
- You have any other medical or mental health condition that the study doctor believes could put you at risk or prevent you from completing the study.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Chris Storgard, MD, Ardea Biosciences, Inc.
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
3 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Number of Subjects With an sUA Level That is < 6.0 mg/dL
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.